LENZ Therapeutics, Inc. Common Stock

LENZNASDAQ • USD
ThemeBiotech - Drug Development›Clinical-Stage Platforms
5.33 USD
↗ 0.28 (5.45%)🟢LIVE (AS OF 10:09 AM EDT)
🟢Market: OPEN

Shares of LENZ Therapeutics, Inc. Common Stock (LENZ) are trading at $5.33. Technical and fundamental signals converge bearish — technicals rate "Sell" while fundamentals read "Sell". Notable factors include a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics place LENZ at a fair price relative to peers.

Technical & fundamental data as of Aug 4, 2026.

Open?$5.10
High?$5.42
Low?$5.03
Prev. Close?$5.05
Volume?122.3K
Avg. Volume?1.0M
VWAP?$5.20
Rel. Volume?0.12x
Bid / Ask
Bid?$5.10 × 100
Ask?$5.13 × 100
Spread?$0.03
Midpoint?$5.12
Valuation & Ratios
Market Cap?158.3M
Shares Out?31.4M
Float?18.3M
Float %?58.3%
P/E Ratio?N/A
P/B Ratio?0.64
EPS?-$3.47
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
Themes
Biotech - Drug Development›Clinical-Stage PlatformsLongevity & Aging›Age-Related Therapeutics
Employees
152
Market Cap
156.6M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.lenz-tx.com
Listed
2024-03-22
Address
201 LOMAS SANTA FE DRIVE, SUITE 300
SOLANA BEACH, CA 92075
Phone: 858-925-7000
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
35
Momentum?
18
Short Sent.?
25
Piotroski F-Score?0/9Weak
Altman Z-Score?1.98Grey
Confidence?58%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?64.94%Squeeze Risk
Short Interest?11.9M
Days to Cover?10.5
Free Float18.3M
Avg Daily Volume1.1M
Settlement Date2026-07-15
Financial Health
Current Ratio?10.40Strong
Quick Ratio?10.26Strong
Cash Ratio?0.96Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.64CHEAP▾
P/S?
Peers
100
S&P
15
7.54HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.1CHEAP▾
EV/Sales?
Peers
100
S&P
25
6.36HIGH▾
Returns & Efficiency
ROE?
S&P
3
-44.2%WEAK▾
ROA?
S&P
3
-40.0%WEAK▾
Cash Flow & Enterprise
FCF?$-87438000
Enterprise Value?$133.6M
Fundamentals ratios updated end of day
MarketsMoversWatchlist